Since the hugely successful 2022 Exosome Based Therapeutic Development Summit, it’s clear that the space is rapidly evolving and is now entering a truly transformational time. As more and more investment pours into the space, the potential applications for exosome therapeutics and their delivery power continue to grow and the huge possibilities are only just starting to unfold.
With key collaborations including $500M IPO for Ilias and HK.inno to co-develop Exosomes and Eli Lilly securing a $1.1B deal with Evox Therapeutics to utilize their IN-NO-vative exosome-based RNA drugs to target the brain, developments like these underscore the potential for exosome-based therapeutics to revolutionize the way we treat diseases.
The 5th event in the series returns with a refreshed program, with data-driven insights from those pioneering the field including Capricor Therapeutics, Aegle Therapeutics, Rion and more who are going to be sharing key learnings alongside 30+ other Global Leaders to enable the successful clinical translation and commercialization of exosome-based therapeutics across a broad range of disease indications.
This is the most comprehensive, end-to-end meeting for industry personnel who are looking to fine-tune molecular components of exosomes, achieve GMP of EVs for clinical applications, and successfully deliver payloads to the target tissue with reduced toxicity. To support the ongoing challenge of exosome characterization, this year features a brand-new focus day on analytical development, diving into characterization assays, purification, and potency assays to enable robust translation into the clinic.
